- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05989360
The Utility of Lung Clearance Index in Ethnic Groups and in Disease (LUCI-ED)
Introduction:
Non-CF, non-PCD bronchiectasis in children is a chronic, suppurative lung disease diagnosed by high resolution computed tomography (HRCT) imaging of the lungs. Spirometry can be abnormal in bronchiectasis but has been shown to be insensitive to early disease in other related conditions such as cystic fibrosis. Lung clearance index (LCI) could have a role in assessment of the disease.
Lung clearance index is calculated from multiple breath washout tests. There are limited data on the normative values expected using some devices, in a range of ages, and between ethnic groups.
The investigators aim to establish normative values in children aged between 6 years and 12 years, to investigate differences between ethnic groups, and to establish the relationship between lung clearance index and other measures of disease in children with bronchiectasis.
Methods:
Healthy children will be recruited from a range of settings and reviewed to ensure no previous lung disease. Children with bronchiectasis diagnosed on HRCT will be recruited from the outpatient service of Birmingham Children's Hospital.
All participants will perform lung function tests including LCI and spirometry. Basic demographic data was collected.
Study Overview
Status
Intervention / Treatment
Detailed Description
Rationale / Hypothesis:
Hypothesis 1
Having established normative ranges helps support interpretation of lung function testing which is key to their value as an investigation. With LCI, it is important to understand the difference that may be expected between children
of different ethnic backgrounds (as demonstrated with other, non-LCI measures of lung function, where important differences between different ethnic groups has been found).
LCI is calculated from an internally adjusted measure of an individual subject's lung volume, therefore potentially negating inherent differences in ethnic variation.
Therefore we hypothesize that there are no differences in LCI in healthy children from differing ethnic backgrounds.
Evidence supporting this hypothesis is not only of intellectual value, but it would also allow clinicians to confidently interpret a range of LCI readings using globally acquired normal values. Should the data not support the hypothesis, an important direction for future research would be established.
Hypothesis 2
LCI has been demonstrated to detect small differences in lung function and correlates well with CT imaging in some disease states. There is a paucity of data in its use in its lung disease outside of CF. Current availability of easy to use, repeatable and reliable devices allows LCI to be measured in the clinic setting (Downing et al. 2016).
Understanding the relationship between CT changes and LCI in younger children with lung disease, would allow a non-invasive investigation (LCI) to be used to guide care and monitor treatment.
In order to understand how LCI changes, we also intend to determine how LCI varies in children with Non-CF, Non-PCD Bronchiectasis over a prolonged period of time.
The investigators hypothesize that in younger children with Non-CF, Non-PCD Bronchiectasis and evidence of milder disease on CT, LCI is a more sensitive disease marker than FEV1, and varies over time.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
West Midlands
-
Birmingham, West Midlands, United Kingdom, B4 6NH
- Birmingham Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy children
Exclusion Criteria:
- Those with underlying respiratory/systemic disease/ prematurity
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: observational
|
Normative values in healthy children from ethnic backgrounds
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Normative values in healthy children
Time Frame: 24 months
|
The normative range of measurements of lung clearance index will be determined
|
24 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Prasad Nagakumar, MD, Birmingham Women's and Children's Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 273069
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bronchiectasis Adult
-
Assiut UniversityNot yet recruitingBronchiectasis | Bronchiectasis Adult | Non-cystic Fibrosis Bronchiectasis | Bronchiectasis With Acute ExacerbationEgypt
-
The First Affiliated Hospital with Nanjing Medical...CompletedBronchiectasis Adult | RadiomicsChina
-
Alexandria UniversityCompletedBronchiectasis Adult | Bronchiectasis with Acute ExacerbationEgypt
-
Synchrony-Medical, LtdRecruitingBronchiectasis AdultUnited States
-
Shanghai Pulmonary Hospital, Shanghai, ChinaRecruitingBronchiectasis AdultChina
-
Ruijin HospitalAstraZeneca Investment (China) Co., LtdNot yet recruitingBronchiectasis AdultChina
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...Fondazione Policlinico Universitario Agostino Gemelli IRCCS; IRCCS Azienda... and other collaboratorsCompleted
-
Fondazione Policlinico Universitario Agostino Gemelli...Active, not recruitingBronchiectasis AdultItaly
-
University of Sao Paulo General HospitalEnrolling by invitation
-
University of Sao Paulo General HospitalFundação de Amparo à Pesquisa do Estado de São PauloCompletedBronchiectasis AdultBrazil
Clinical Trials on Lung Clearance Index
-
Assistance Publique - Hôpitaux de ParisURC-CIC Paris Descartes Necker Cochin; Vaincre la MucoviscidoseCompleted
-
National Jewish HealthCompletedBronchiolitis | Dyspnea | PneumonitisUnited States
-
National Jewish HealthActive, not recruitingChronic Lung DiseaseUnited States
-
Central Hospital, Nancy, FranceRecruiting
-
Indiana UniversityCompleted
-
University of ZurichWithdrawnLung Transplantation | Chronic Lung Allograft Dysfunction | Rejection Lung Transplant
-
University of North Carolina, Chapel HillNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)TerminatedCystic FibrosisUnited States
-
Tanta UniversityEnrolling by invitationProstate | Lung Ultrasound Score | Transurethral Resection (TUR) SyndromeEgypt
-
Istanbul University - Cerrahpasa (IUC)WithdrawnCovid19 | Respiratory Distress Syndrome, Adult | Pulmonary Edema | Ventilation Perfusion MismatchTurkey
-
The Hospital for Sick ChildrenRecruitingAsthma | Cystic FibrosisCanada